Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Exploratory Efficacy Study of Guaifenesin in Upper Back Pain

N/ACompletedNCT01562548
GlaxoSmithKline78 enrolled

Overview

Explore the clinical efficacy of 7-day treatment regimens of guaifenesin in order to investigate the evidence that guaifenesin is an effective treatment for upper back/neck/shoulder muscle spasm/stiffness and pain.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

78

Conditions

Upper Back Pain

Interventions

GuaifenesinDRUG

high and low dose of Guaifenesin each given twice daily over a 4-day treatment period

PlaceboDRUG

no active ingredient

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years
Medical Language ↔ Plain English
Inclusion Criteria: * Paticipant presents with a new episode of acute upper back/neck/shoulder pain and muscle spasm that: 1. is at least 30 days from previous episode. 2. has an onset occurred within 48 hours of Visit 1. 3. has symptoms consistent with a clinical diagnosis as per the physical examination at Visit 1. 4. has a subject-rated muscle spasm score and a pain score of at least 40 out of 100 on a 100mm VAS. * Paticipant has a normal neurological examination. Exclusion Criteria: * Medical history: a) Paticipant has a known or suspected intolerance or hypersensitivity to guaifenesin or methocarbamol (or closely related compounds) or any of their stated ingredients. b) Paticipant has history of upper back pain with active hypersensitive spots - trigger point in the muscles of upper back/neck/shoulder/maxillofacial regions. c) Paticipant has a current or recent history of liver and/or kidney disease, neck/back/shoulder injuries, spinal disc disease, myocardial infarction (\<12 months from Visit 1) and osteoporosis. d) Subjects have history of other chronic pain e.g. headache, osteoarthritis, arthritis, lower back pain etc. * Medications: a) Paticipant has used a muscle relaxant or narcotic within 2 weeks of Visit 1. b) Paticipant has used monoamine oxidase inhibitors or selegiline within 2 weeks of Visit 1 c) Currently using tricyclic antidepressants, lithium, anticoagulants, or tramadol. * Paticipant is involved in a workers compensation case. * Paticipant is unlikely to refrain from using analgesics, NSAIDs, and other muscle relaxants for the duration of the study, with the exception of cardioprotective doses of aspirin (i.e., ≤ 325 mg/day). * Paticipant is unlikely to refrain from physical therapy, massage therapy, acupuncture, heat treatment, spas, etc for the duration of the study.

Locations (5)

Med Investigations

Fair Oaks, California, United States

San Diego Sports Medicine and Family Health Center

San Diego, California, United States

Radiant Research - Cincinnati

Cincinnati, Ohio, United States

Radiant Research, Inc. - TX

San Antonio, Texas, United States

J. Lewis Research

Salt Lake City, Utah, United States

Outcomes

Primary Outcomes

Mean Change From Baseline of Both AM and PM Spasm Assessment Scores

The score was measured as 'assessment at baseline' minus 'assessment after treatment' over 7 day period (mean of all AM and PM changes from baseline). Measurements were based on an 11 categorical Numerical Rating Scale (NRS) with a range from 0 - no spasm to 10 - unbearable spasm.

Time frame: 7 Days

Secondary Outcomes

Mean Change From Baseline of Both AM and PM NRS Muscle Stiffness Assessment Scores

The score was measured as 'assessment at baseline' minus 'assessment after treatment' over 7 day period (mean of all AM and PM changes from baseline). Measurements were based on an 11 categorical Numerical Rating Scale (NRS) with a range from 0 - no stiffness to 10 - unbearable stiffness.

Time frame: 7 Days

Mean Change From Baseline of Both AM and PM NRS Tension Assessment Scores

The score was measured as 'assessment at baseline' minus 'assessment after treatment' over 7 day period (mean of all AM and PM changes from baseline). Measurements were based on an 11 categorical Numerical Rating Scale (NRS) with a range from 0 - no tension to 10 - unbearable tension.

Time frame: 7 Days

Mean Change From Baseline of Both AM and PM NRS Pain Assessment Scores

The score was measured as 'assessment at baseline' minus 'assessment after treatment' over 7 day period (mean of all AM and PM changes from baseline). Measurements were based on an 11 categorical Numerical Rating Scale (NRS) with a range from 0 - no pain to 10 - unbearable pain.

Time frame: 7 Days

Mean Change From Baseline of Both AM and PM NRS Discomfort Assessment Scores

The score was measured as 'assessment at baseline' minus 'assessment after treatment' over 7 day period (mean of all AM and PM changes from baseline). Measurements were based on an 11 categorical Numerical Rating Scale (NRS) with a range from 0 - no discomfort to 10 - unbearable discomfort.

Time frame: 7 Days

Muscle Relaxation Scores

The score was measured as mean of both AM and PM assessment scores at Days 4 and 7. Measurements were based on a 5 categorical scale: 0 - no relaxation, 1- a little relaxation, 2 - fair relaxation, 3 - good relaxation, 4 - complete muscle relaxation.

Time frame: 4 Days, 7 Days

Upper Back/Neck/Shoulder Pain Disability (Vernon-Mior) Index Scores

Vernon-Mior upper back/neck/shoulder components were assessed before the treatment and at Days 4 and 7. Each component (pain intensity, personal care, lifting, reading, headaches, concentration, work, driving, sleeping, and recreation) was assessed based on a 6-point categorical scale (1 to 6), with 1 being the most positive and 6 being the worst.

Time frame: Before treatment, 4 Days, 7 Days

Global Assessment of Treatment Helpfulness (GATH)

Measured as an overall qualitative score on a 5 point categorical scale: 0-poor, 1-fair, 2-good, 3-very good and 4-excellent.

Time frame: 4 Days, 7 Days

Global Assessment of Sleep Disturbance (GASD)

Categorized after treatment as: 'decreased', 'increased' or 'stayed the same'.

Time frame: 7 Days

Global Assessment of Headache Frequency (GAHF)

Categorized after treatment as: 'decreased', 'increased' or 'stayed the same'.

Time frame: 7 Days

Global Assessment of Headache Intensity (GAHI)

Categorized after treatment as: 'decreased', 'increased' or 'stayed the same'.

Time frame: 7 Days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.